

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



June 24, 2020

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
NSE Code: SUNPHARMA

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.
Stock Code: 524715

Dear Sirs,

Sub: Intimation under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the details of related party transactions on consolidated basis for the half year ended March 31, 2020 in the format specified in the relevant accounting standards for annual results.

This is for your information and record.

Thanking you,

Yours faithfully,
For Sun Pharmaceutical Industries Limited

Ashok I. Bhuta
Compliance Officer

Encl: As above

SUN PHARMACEUTICAL INDUSTRIES LIMITED

Related Party disclosure on a consolidated basis - Half year ended March 31, 2020

Names of related parties where there are transactions and description of relationships**a Key Management Personnel (KMP)**

Dilip Shantilal Shanghvi	Managing Director
Sudhir Vrundavandas Valia	Non-Executive Director (Designation changed from Whole-time Director to Non-Executive Director on May 29, 2019) and Non-Independent Director
Sailesh Trambaklal Desai	Wholetime Director
Israel Makov	Chairman and Non- Executive Director (Non- Independent)
Kalyanasundaram Iyer Natesan Subramanian	Wholetime Director

b Relatives of Key Management Personnel

Aalok Shanghvi
Vidhi Shanghvi

c Others (Entities in which the KMP and Relatives of KMP have control or significant influence)

Aditya Medisales Limited
Alfa Infraprop Private Limited
Makov Associates Limited
PV Power Technologies Private Limited
Shanghvi Finance Private Limited
Shantilal Shanghvi Foundation
Sidmak Laboratories (India) Private Limited
Sun Petrochemicals Private Limited
Sun Pharma Advanced Research Company Limited
United Medisales Private Limited

d Joint Venture

Artes Biotechnology GmbH

e Associates

Medinstill LLC
Medinstill Development LLC
Dy Py Institute LLC

f Unconsolidated Subsidiary

Foundation for Disease Elimination and Control of India

SUN PHARMACEUTICAL INDUSTRIES LIMITED

Transactions during half year ended March 31, 2020 with related parties :	₹ In Million
	Half Year ended March 31, 2020
Purchase of goods	148.2
Others	148.2
Purchase of property, plant and equipment and other intangible assets	34.0
Others	34.0
Acquired on Slump sale basis	629.6
Others	629.6
Revenue from contracts with customers, net of returns	91.9
Others	91.9
Sale of property, plant and equipment and other intangible assets	0.9
Others	0.9
Receiving of service	635.9
Others	618.5
Joint venture	17.4
Reimbursement of expenses - Paid	20.0
Associate	13.3
Others	6.7
Rendering of service	146.3
Others	146.3
Reimbursement of expenses - Received	48.7
Others	48.7
Loan given	0.8
Associate	0.8
Lease Rental and hire charges (Income)	11.3
Others	11.3
Rent expense / Payment towards Lease Liabilities	3.9
Others	3.9
Remuneration/ compensation	227.2
Key management personnel	214.6
Relatives of Key management personnel	12.6
Donation	36.9
Unconsolidated subsidiary	29.8
Others	7.1

NOTE :

- The figures for the half year ended March 31, 2020 are the balancing figures between the figures in respect of full financial year and the published year to date figures for the half year ended September 30, 2019.
- Key management Personnel (KMP) and Relatives of KMP who are under the employment of the Company are entitled to post employment benefits and other long term employee benefits recognised as per Ind AS 19 - 'Employee Benefits'. As these employee benefits are lump sum amount provided on the basis of actuarial valuation, the same is not included above and there is no Share-based payments to key management personnel and relatives of KMP.